Cargando…

A Risk-Factor Model for Antineoplastic Drug-Induced Serious Adverse Events in Cancer Inpatients: A Retrospective Study Based on the Global Trigger Tool and Machine Learning

The objective of this study was to apply a machine learning method to evaluate the risk factors associated with serious adverse events (SAEs) and predict the occurrence of SAEs in cancer inpatients using antineoplastic drugs. A retrospective review of the medical records of 499 patients diagnosed wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Ni, Pan, Ling-Yun, Chen, Wan-Yi, Ji, Huan-Huan, Peng, Gui-Qin, Tang, Zong-Wei, Wang, Hui-Lai, Jia, Yun-Tao, Gong, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9277092/ https://www.ncbi.nlm.nih.gov/pubmed/35847000 http://dx.doi.org/10.3389/fphar.2022.896104

Ejemplares similares

Adverse drug events in Chinese pediatric inpatients and associated risk factors: a retrospective review using the Global Trigger Tool
por: Ji, Huan-huan, et al.
Publicado: (2018)

Predicting Adverse Drug Events in Chinese Pediatric Inpatients With the Associated Risk Factors: A Machine Learning Study
por: Yu, Ze, et al.
Publicado: (2021)

Promising Antineoplastic Actions of Melatonin
por: Favero, Gaia, et al.
Publicado: (2018)

Serious Adverse Events Reporting in Phase III Randomized Clinical Trials of Colorectal Cancer Treatments: A Systematic Analysis
por: Yao, Yanhong, et al.
Publicado: (2021)

Adverse drug events in Chinese elder inpatients: a retrospective review for evaluating the efficiency of the Global Trigger Tool
por: Yu, Nan, et al.
Publicado: (2023)

Human papillomavirus vaccine-associated premature ovarian insufficiency and related adverse events: data mining of Vaccine Adverse Event Reporting System
por: Gong, Li, et al.
Publicado: (2020)

Characterization of adverse drug events identified by trigger in Brazilian pediatric inpatients()
por: Silva, Lunara Teles, et al.
Publicado: (2019)

Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients: Nivolumab-related serious/fatal adverse events
por: Zhao, Bin, et al.
Publicado: (2018)

Serious Adverse Drug Reactions and Safety Signals in Children: A Nationwide Database Study
por: Vieira, Jean Mendes de Lucena, et al.
Publicado: (2020)

Fluid retention-associated adverse events in patients treated with BCR::ABL1 inhibitors based on FDA Adverse Event Reporting System (FAERS): a retrospective pharmacovigilance study
por: Huang, Jing, et al.
Publicado: (2023)

Serious Neurological Adverse Events of Ceftriaxone
por: Lacroix, Clémence, et al.
Publicado: (2021)

Analysis of 12 cases of antineoplastic agents-induced interstitial lung disease
por: Li, Xiao, et al.
Publicado: (2023)

Generalizability of machine learning methods in detecting adverse drug events from clinical narratives in electronic medical records
por: Zitu, Md Muntasir, et al.
Publicado: (2023)

Adverse Event Profiles of PARP Inhibitors: Analysis of Spontaneous Reports Submitted to FAERS
por: Tian, Xiaojiang, et al.
Publicado: (2022)

Commentary: Adverse event profiles of PARP inhibitors: analysis of spontaneous reports submitted to FAERS
por: Schilder, Jeanne M., et al.
Publicado: (2023)

Impact of Plasma Exposure of Statins and Their Metabolites With Major Adverse Cardiovascular Events in Chinese Patients With Coronary Artery Disease
por: Zhou, Xiao-hong, et al.
Publicado: (2020)

Identifying and Characterizing Serious Adverse Drug Reactions Associated With Drug-Drug Interactions in a Spontaneous Reporting Database
por: Magro, Lara, et al.
Publicado: (2021)

Identification of serious, unpredictable adverse events with tocilizumab
Publicado: (2020)

Addition of metformin for non-small cell lung cancer patients receiving antineoplastic agents
por: Wang, Yan, et al.
Publicado: (2023)

Indication and adverse event profiles of denosumab and zoledronic acid: based on U.S. FDA adverse event reporting system (FAERS)
por: Su, Si, et al.
Publicado: (2023)

First use of antineoplastic agents in women with breast cancer in the state of Rio de Janeiro, Brazil
por: dos Santos, Ranailla Lima Bandeira, et al.
Publicado: (2023)

Evaluation of the Direct Costs of Managing Adverse Drug Events in all Ages and of Avoidable Adverse Drug Events in Older Adults in Japan
por: Katsuno, Hayato, et al.
Publicado: (2021)

Neurological Adverse Events Associated With Esketamine: A Disproportionality Analysis for Signal Detection Leveraging the FDA Adverse Event Reporting System
por: Guo, Haoning, et al.
Publicado: (2022)

Ocular adverse events associated with anti-VEGF therapy: A pharmacovigilance study of the FDA adverse event reporting system (FAERS)
por: Ma, Pan, et al.
Publicado: (2022)

Adverse drug events in the prevention and treatment of COVID-19: A data mining study on the FDA adverse event reporting system
por: Guo, Qiang, et al.
Publicado: (2022)

Adverse events associated with molnupiravir: a real-world disproportionality analysis in food and drug administration adverse event reporting system
por: Liang, Yankun, et al.
Publicado: (2023)

Risk of major adverse events associated with gabapentinoid and opioid combination therapy: A systematic review and meta-analysis
por: Hahn, Jongsung, et al.
Publicado: (2022)

Describing adverse events in Swiss hospitalized oncology patients using the Global Trigger Tool
por: Gerber, Anne, et al.
Publicado: (2020)

Spontaneous Reports of Serious Adverse Drug Reactions Resulting From Drug–Drug Interactions: An Analysis From the French Pharmacovigilance Database
por: Létinier, Louis, et al.
Publicado: (2021)

Corrigendum: Neurological adverse events associated with esketamine: A disproportionality analysis for signal detection leveraging the FDA adverse event reporting system
por: Guo, Haoning, et al.
Publicado: (2022)

Potential Adverse Events Reported With the Janus Kinase Inhibitors Approved for the Treatment of Rheumatoid Arthritis Using Spontaneous Reports and Online Patient Reviews
por: Song, Yun-Kyoung, et al.
Publicado: (2022)

Variation in adverse drug events of opioids in the United States
por: Liu, Edward Y., et al.
Publicado: (2023)

Serious adverse events associated with yellow fever vaccine
por: de Menezes Martins, Reinaldo, et al.
Publicado: (2015)

Analysis of serious adverse event: Writing a narrative
por: Nambiar, Indu
Publicado: (2018)

Hyperuricaemia, gout and related adverse events associated with antihypertensive drugs: A real-world analysis using the FDA adverse event reporting system
por: Jiao, Xue-Feng, et al.
Publicado: (2023)

Correction to: Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients
por: Zhao, Bin, et al.
Publicado: (2019)

The Off-Label Use of Antineoplastics in Oncology Is Limited But Has Notable Scientific Support in a University Hospital Setting
por: Herrero Fernandez, Marta, et al.
Publicado: (2019)

Post-marketing safety surveillance of dalfampridine for multiple sclerosis using FDA adverse event reporting system
por: Xiong, Rui, et al.
Publicado: (2023)

Bevacizumab Dose Affects the Severity of Adverse Events in Gynecologic Malignancies
por: Lee, Shu-Ping, et al.
Publicado: (2019)

Current landscape and tailored management of immune-related adverse events
por: Liu, Wenhui, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_702q108mjfcf5kvq65r616jd7k